| Today’s Big NewsOct 2, 2023 |
| By Ayla Ellison The Fierce 50 special report shines a spotlight on 50 remarkable individuals and organizations reshaping biopharma and healthcare. Explore their profiles across five categories, each representing a pivotal aspect of the industry. |
|
|
|
By Fraiser Kansteiner The FDA has rejected Lilly’s investigational atopic dermatitis treatment lebrikizumab over findings uncovered during the inspection of a third-party contract manufacturing organization. |
By Nick Paul Taylor Discoveries that enabled mRNA vaccines against COVID-19 have landed two scientists a Nobel Prize. The Nobel Assembly awarded Katalin Karikó and Drew Weissman the prize for their work on nucleoside base modifications, which underpinned the Moderna and Pfizer-BioNTech vaccines that changed the course of the pandemic. |
By Andrea Park Nearly a year after Medtronic announced its intent to spin out its patient monitoring and respiratory interventions divisions, the business units have reportedly found a buyer. |
|
Tuesday, October 3, 2023 | 11am ET / 8am PT The life science industry has been growing rapidly. As a result, many biopharma companies are choosing to outsource their analytical method development and testing to CDMOs to fully meet their objectives and foster innovation. Join us to take a deep dive into these critical partnerships and learn key actionable insights. Register now. 
|
|
By Fraiser Kansteiner ICER submitted a special report to CMS weighing evidence on Bristol Myers Squibb and Pfizer’s Eliquis and Bayer and Johnson & Johnson’s Xarelto to treat nonvalvular atrial fibrillation (NVAF), the condition where both drugs garner most of their prescriptions. With the appraisals, ICER hopes to influence upcoming Medicare price negotiations. |
By Gabrielle Masson The draw of Flagship Pioneering strikes again. After leaving his position as GSK’s head of R&D, John Lepore, M.D., is set to become a CEO-partner at Flagship and will helm the portfolio company’s ProFound Therapeutics. |
By Andrea Park A new medtech-pharma collaboration has its eye on catching retinal diseases as early as possible and staving them off with precise, personalized treatments. |
By Kevin Dunleavy Two days after filing a lawsuit questioning the constitutionality of drug-price negotiations in the Inflation Reduction Act, Novo Nordisk has grudgingly signed on to the program. In addition, an Ohio court rejected a U.S. Chamber of Commerce attempt to block the start of the program. |
By James Waldron With VC firms Forbion and BioGeneration Ventures announcing their largest biopharma funds to date this year, how is investor interest in European biotechs holding up? |
By Conor Hale While the act of parsing DNA for an inherited, cancer-linked mutation is nothing new, the scale offered by Invitae’s test has defined a new product category going forward, the agency said. |
By Eric Sagonowsky Novo Nordisk is gearing up to launch its new rare disease offering in early 2024. Rivfloza, a product of the company's Dicerna buyout, will go up against Alnylam's Oxlumo. |
By Gabrielle Masson Novartis’ investigational oral factor B inhibitor has hit its early target in a phase 3 kidney disorder trial, a success that has the pharma readying to submit a request for fast-track FDA approval next year. |
Fierce podcasts Don’t miss an episode |
| In this episode of "The Top Line," Fierce Pharma's Eric Sagonowksy talks with Pam Cheng, the AstraZeneca executive who is playing a key role in driving the company's sustainability ambitions. |
|
|---|
|
|
|
Thursday, October 12, 2023 | 2pm ET / 11am PT In this webinar, we take a deep dive into different strategies for unifying enterprise-wide lab data. You'll learn how to drive better access, collaboration, and AI-driven insight. Don't miss out, register today. 
|
|
Webinar Embark on an in-depth journey through the pivotal Make-Test-Decide Workflow, where collaboration and data-driven decisions play a paramount role in the intricate landscape of drug discovery. Watch now to learn how cloud implementation fosters accessibility and collaboration, revolutionizing research across locations and companies. Sponsored by: Revvity Signals |
eBook Learn how to get better results from suboptimal biospecimens for NGS and protein analysis. Sponsored by: Covaris |
Whitepaper Economic and regulatory factors are making biopharma supply chains more complex in the EU. This paper explores strategies that biopharma companies can use to better manage complexity, cost, and risk. Presented by: AIM, the supply chain leader for life science entrants and midsize life science companies |
Whitepaper From Assay Development Through Large Molecule Development. Streamline your R&D workflows and gain valuable insights with our Biology Solutions Brochure. Download now to discover how to control your laboratory workflows across various assay techniques, modalities, and data types. Sponsored by: Revvity Signals |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
Whitepaper Learn how outsourcing the buffer preparation can reallocate resources to support core activities of your bioprocess production. Sponsored by: Thermo Fisher Scientific |
Whitepaper From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
Whitepaper By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
| |
|
